Health
Penn Study Finds Solid-Tumor Cancer Patients Ineligible for Clinical Trials Receive Immunotherapy at Greater Rates Despite Lack of Benefits – Newswise
Cancer patients who are ineligible for clinical trials receive immune checkpoint inhibitors (ICI) at greater rates than patients…
Newswise — PHILADELPHIA — Cancer patients who are ineligible for clinical trials receive immune checkpoint inhibitors (ICI) at greater rates than patients who are trial eligible despite no survival benefit, according to a new study by researchers at the…
Continue Reading